Nanopharmaceutics (Nanopharmaceutics) EV-to-EBIT : -93.80 (As of Apr. 28, 2024)

Nanopharmaceutics EV-to-EBIT Chart

Nanopharmaceutics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EV-to-EBIT	Get a 7-Day Free Trial						-11.83	-39.47	-99.51	-72.42	-208.92

Competitive Comparison of Nanopharmaceutics's EV-to-EBIT

For the Biotechnology subindustry, Nanopharmaceutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanopharmaceutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanopharmaceutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nanopharmaceutics's EV-to-EBIT falls into.

Nanopharmaceutics EV-to-EBIT Calculation

Nanopharmaceutics's EV-to-EBIT for today is calculated as:

Nanopharmaceutics's current Enterprise Value is $104.40 Mil.
Nanopharmaceutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics  (OTCPK:TGRP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nanopharmaceutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2018 is calculated as:

Nanopharmaceutics's Enterprise Value for the quarter that ended in Sep. 2018 was $232.52 Mil.
Nanopharmaceutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanopharmaceutics (Nanopharmaceutics) Business Description